Valent BioSciences offers both reach and flexibility in establishing new R&D partnerships. Our global presence gives us the ability to collaborate in a geographically distinct manner. Our expertise also affords us the ability to collaborate within a single market space, such as Agriculture, Public Health, Forest Health, Professional, and Consumer products. This reach and flexibility across both geographies and markets creates an attractive environment for new R&D partners.
There are many reasons our partners have chosen to work with VBC. Since we have a relatively specialized portfolio, existing products have less risk of overlap. VBC also has a hunger for new opportunities, including niche markets. In agriculture, our focus and commitment to specialty crops gives us the capability to look at projects with smaller sales potential provided customer need and Return On Investment (ROI) potential can be validated.
VBC uses the following criteria when evaluating potential R&D partnerships:
- Customer needs – current and future
- Fit with VBC strategic objectives and core competencies
- Product safety/ risk profile
- Product performance and efficacy
- Product profitability
- Market size and potential position
- Proprietary aspects: patents, exclusivity, manufacturing
- Development/ regulatory risk: time & cost to launch
VBC considers out-licensing opportunities with interested partners an important strategic objective. Whether it pertains to accessing our extensive microbial strain library, patents, or other proprietary corporate assets, VBC recognizes that others may derive complementary and/or synergistic value from our technologies under the appropriate agreement.
With unparalleled knowledge of biorational products and a demonstrated competence in developing and registering traditional chemistry, VBC has a history of being a successful and reliable development partner. We have longstanding collaborative relationships with key influencers/customers in specific segments. Collaborations include Pace International LLC, Lomon Biotechnology Company, EMBRAPA, the National Research Council of Canada’s Plant Biotechnology Institute (NRC-PBI), and many others that, in agreement with our partners, are subject to secrecy provisions.